HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Prostacyclin

HCID 5282411
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
35121-78-9
Standard SMILES
CCCCC[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)O[C@H]2C[C@H]1O
InChIKey
KAQKFAOMNZTLHT-OZUDYXHBSA-N
Molecular formula
C20H32O5
Average molar mass
352.5 g/mol
Monoisotopic mass
352.22497412

Overview

Prostaglandin I2 is a prostaglandins I. It has a role as a mouse metabolite. It is a conjugate acid of a prostaglandin I2(1-).

Names & identifiers

Preferred name
Prostacyclin
IUPAC
(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
English name
Epoprostenol
Molecular formula
C20H32O5
Molecular weight
352.47

Names & synonyms

epoprostenolprostacyclinprostaglandin I235121-78-9VasocyclinProstaglandin XPGI2EpoprostenolumACT-385781ADCR9Z582X0U-53217(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
Show more names
PGXPGl2U 53217U-53217ACyclo-ProstinProstaglandinI(+)-AlismoxideProstaglandin l2
(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acidU-53,217DTXSID5022988CHEBI:155526,9S-epoxy-11R,15S-dihydoxy-5Z,13E-prostadienoic acidEpoprostanol(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoateProsta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9alpha,11alpha,13E,15S)-

Database identifiers

CAS
35121-78-9
PubChem CID
5282411
DTXSID
DTXSID5022988

Properties

Computed structural propertiesFilling in

XLogP
2.9
Topological polar surface area
87 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
5
Rotatable bonds
10
Heavy atoms
25
Formal charge
0
Complexity
484

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
LipidsFatty Acyls [FA] -> Eicosanoids [FA03] -> Prostaglandins [FA0301]
Human DrugsBreast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Cardiovascular Agents; Prostaglandins, Synthetic; Vasodilator Agents
Physical DescriptionSolid
Collision Cross Section · 3 items

198.6 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

201.3 Ų [M+H]+ [CCS Type: DT; Method: stepped-field]

199.8 Ų [M+H]+

Physicochemical properties

Boiling point
530.2 · 530.2±50.0 °C(Predicted)
Density
1.221 · 1.221
pka
4.7 · 4.70±0.10(Predicted)
FDA UNII
9 Z582X0 · DCR9Z582X0

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Chemistry & industry

Pharmacology

ATC Code · 3 items

B01AC09

B - Blood and blood forming organs

QB - Blood and blood forming organs

Pharmacodynamics · 1 item

Epoprostenol has two major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. The effect of epoprostenol on heart rate in animals varies with dose. At low doses, there is vagally mediated brudycardia, but at higher doses, epoprostenol causes reflex tachycardia in response to direct vasodilation and hypotension. No major effects on cardiac conduction have been observed. Additional pharmacologic effects of epoprostenol in animals include bronchodilation, inhibition of gastric acid secretion, and decreased gastric emptying. No available chemical assay is sufficiently sensitive and specific to assess the in vivo human pharmacokinetics of epoprostenol.

Mechanism of Action · 1 item

Prostaglandins are present in most body tissues and fluids and mediate many biological functions. Epoprostenol (PGI2) is a member of the family of prostaglandins that is derived from arachidonic acid. The major pharmacological actions of epoprostenol is ultimately inhibition of platelet aggregation. Prostacycline (PGI2) from endothelial cells activate G protein-coupled receptors on platelets and endothelial cells. This activation causes adenylate cyclase to produce cyclic AMP which inhibits further platelet activation and activates protein kinase A. Cyclic AMP also prevents coagulation by preventing an increase in intracellular calcium from thromboxane A2 binding. PKA then continues the cascade by phosphorylating and inhibiting myosin light-chain kinase which leads to smooth muscle relaxation and vasodilation. Notably, PGI2 and TXA2 work as physiological antagonists.

Biological Half-LifeThe in vitro half-life of epoprostenol in human blood at 37°C and pH 7.4 is approximately 6 minutes; the in vivo half-life of epoprostenol in humans is therefore expected to be no greater than 6 minutes.
Metabolism/Metabolites

Related reactions

4 records
New reaction record
HRID 483261 reaction equation
HRID 483261As reactant
HRID 1708154 reaction equation
HRID 1708154As reactant
HRID 1881348 reaction equation
HRID 1881348As reactant
HRID 1908709 reaction equation
HRID 1908709As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
ChEMBL
CHEMBL1139
ChEBI
CHEBI:15552
UNII
DCR9Z582X0
Nikkaji
J17.550A
· 1 item

Epoprostenol is metabolized to 2 primary metabolites: 6-keto-PGF1α (formed by spontaneous degradation) and 6,15-diketo-13,14-dihydro-PGF1α (enzymatically formed), both of which have pharmacological activity orders of magnitude less than epoprostenol in animal test systems. Fourteen additional minor metabolites have been isolated from urine, indicating that epoprostenol is extensively metabolized in humans.

FDA Pharmacological Classification · 6 items

DCR9Z582X0

EPOPROSTENOL

Established Pharmacologic Class [EPC] - Prostacycline Vasodilator

Chemical Structure [CS] - Prostaglandins I

Physiologic Effects [PE] - Vasodilation

Epoprostenol is a Prostacycline Vasodilator. The physiologic effect of epoprostenol is by means of Vasodilation.

MeSH Pharmacological Classification · 2 items

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Absorption, Distribution and Excretion · 2 items

Epoprostenol is metabolized to 2 primary metabolites: 6-keto-PGF1α (formed by spontaneous degradation) and 6,15-diketo-13,14-dihydro-PGF1α (enzymatically formed), both of which have pharmacological activity orders of magnitude less than epoprostenol in animal test systems. Fourteen additional minor metabolites have been isolated from urine, indicating that epoprostenol is extensively metabolized in humans.

357 mL/kg

Tissue LocationsAdipose Tissue
Cellular LocationsEndoplasmic reticulum
Metabolite PathwaysAcetaminophen Action Pathway

Applications

UsesInhibitor (platelet). [Names previously used: Prostacyclin, PGI2, Prostagland in I2, Prostaglandin X, PGX].

Upstream & downstream products

Upstream raw materials

Potassium tert-butoxide

Additional notes

DefinitionChEBI: Prostaglandin I2 is a prostaglandins I. It has a role as a mouse metabolite. It is a conjugate acid of a prostaglandin I2(1-).